VolitionRx Highlights Sepsis Biomarker Breakthrough with Nu.Q NETs Assay

VolitionRx Limited (NYSE American: VNRX) is advancing the fight against sepsis with its Nu.Q NETs assay, a biomarker test that detects NETosis, a cell death process linked to severe inflammation. The company has released an educational video featuring Critical Care Lead and Medical Consultant Dr. Andrew Retter, while highlighting a growing body of peer-reviewed studies that demonstrate the Nu.Q H3.1 test's ability to distinguish sepsis from non-infectious inflammation, correlate with disease severity, and predict outcomes such as organ failure and mortality. VolitionRx believes this low-cost nucleosome quantification technology could revolutionize sepsis management by enabling personalized care, identifying elevated H3.1 nucleosome levels as a treatable trait, and informing future therapeutic strategies.

VolitionRx, a multinational company focused on epigenetics, is developing simple, cost-effective blood tests for early detection and monitoring of life-altering diseases, including cancers and sepsis. The company's research and development activities are centered in Belgium, with an innovation lab in the U.S. and an office in London. The growing evidence base for the Nu.Q NETs assay spans multiple countries and patient populations, reinforcing its potential as a critical tool in the clinical setting.

The full press release is available at https://ibn.fm/2IH3m. For more information, visit the company's website at https://volition.com/. Media enquiries can be directed to Louise Batchelor at mediarelations@volition.com.